These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9834828)

  • 1. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas.
    Garcia AA; Kempf RA; Rogers M; Muggia FM
    Ann Oncol; 1998 Oct; 9(10):1131-3. PubMed ID: 9834828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
    Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
    Chidiac T; Budd GT; Pelley R; Sandstrom K; McLain D; Elson P; Crownover R; Marks K; Muschler G; Joyce M; Zehr R; Bukowski R
    Invest New Drugs; 2000 Aug; 18(3):253-9. PubMed ID: 10958594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
    Samantas E; Kalofonos H; Linardou H; Nicolaides C; Mylonakis N; Fountzilas G; Kosmidis P; Skarlos D
    Ann Oncol; 2000 Nov; 11(11):1395-7. PubMed ID: 11142478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
    Skubitz KM
    Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
    Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
    Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
    Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
    J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
    Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
    Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
    Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
    J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
    Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
    Caponigro F; Comella P; Budillon A; Bryce J; Avallone A; De Rosa V; Ionna F; Comella G
    Ann Oncol; 2000 Mar; 11(3):339-42. PubMed ID: 10811502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
    J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.
    Pisters PW; Patel SR; Prieto VG; Thall PF; Lewis VO; Feig BW; Hunt KK; Yasko AW; Lin PP; Jacobson MG; Burgess MA; Pollock RE; Zagars GK; Benjamin RS; Ballo MT
    J Clin Oncol; 2004 Aug; 22(16):3375-80. PubMed ID: 15310783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.